Skip to main content
SpringerLink
Log in

Azimilide for Atrial Fibrillation: Clinical Trial Results and Implications

  • Published:
Cardiac Electrophysiology Review

Abstract

Azimilide dihydrochloride (or azimilide) is a class III antiarrhythmic drug currently under investigation that has been tested in atrial fibrillation in four randomized, placebo-controlled clinical trials to assess efficacy and dose range. These investigational trials showed that doses of azimilide 100 and 125 mg once daily prolonged the time to symptomatic arrhythmia recurrence in patients with a history of symptomatic atrial fibrillation, atrial flutter or both. Doses of 75 mg or less were not useful in this indication.

Safety of azimilide has been examined in several different types of studies. In a large randomized clinical trial of post-infarct patients, azimilide neither increased nor decreased mortality risk. In patients with supraventricular arrhythmias, the most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Infrequent cases of torsade de pointes and severe neutropenia were reported in patients taking azimilide.

Azimilide is an investigational antiarrhythmic drug that has shown efficacy in patients with atrial fibrillation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pritchett ELC. Azimilide: A review of clinical studies. In: Tse H-F, Lee KLF, Lau C-P, eds. Bologna, Italy: Monduzzi Editore, 2003:945-952.

    Google Scholar 

  2. Salata JJ, Brooks RR. Pharmacology of Azimilide Dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovascular Drug Reviews 1997;15:137-156.

    Google Scholar 

  3. Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello S, Pritchett ELC. Dose-response relationships of azimilide in the management of symptomatic, recurrent atrial fibrillation. Am J Cardiol 2001;88(9):974-979.

    Google Scholar 

  4. Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell D, Pritchett ELC, Azimilide Supraventricular Arrhythmia Program Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. Am Heart J 2002;143:643-649.

    Google Scholar 

  5. Pritchett ELC, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE, Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Antiarrhythmic effects of azimilide in atrial fibrillation. Efficacy and doseresponse. J AmColl Cardiol 2000;36:794-802.

    Google Scholar 

  6. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC, and the Flecainide Supraventricular Tachycardia Study Group. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-1570.

    Google Scholar 

  7. Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi H, Spyt M, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM. Azimilide Post Infarct Survival Evaluation (ALIVE): Azimilide does not affect mortality in post-myocardial infarction patients. Circulation 2001;104(25):104.

    Google Scholar 

  8. Pratt CM, Singh BN, Al-Khalidi H, Brum JM, Holroyde MJ, De Ferrari GM, Schwartz PJ, Matteo PS, Camm AJ. Efficacy of azimilide in treatment of atrial fibrillation in a high-risk post-myocardial infarction population. Circulation 2002;106-II(19):634.

    Google Scholar 

  9. Torp-Pederson C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Vidabaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341(12):857-865.

    Google Scholar 

  10. Pritchett ELC, Schulte MC, Schnell D, Marcello SR, Wilkinson WE, Page RL, Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. J Clin Pharm 2002;42(4):388-394.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Clinical Pharmacology and Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina and Procter &

    Edward L.C. Pritchett & Stephen R. Marcello

  2. Gamble Pharmaceuticals, Cincinnati, OH, USA

    Edward L.C. Pritchett & Stephen R. Marcello

Authors
  1. Edward L.C. Pritchett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen R. Marcello
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pritchett, E.L., Marcello, S.R. Azimilide for Atrial Fibrillation: Clinical Trial Results and Implications. Card Electrophysiol Rev 7, 215–219 (2003). https://doi.org/10.1023/B:CEPR.0000012385.15778.d2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CEPR.0000012385.15778.d2

Search

Navigation